Infectious Disease Point-of-care (POC) Diagnostics 2020 Global Share, Trend, Segmentation And Forecast To 2028

0
0

A new market study, titled “Infectious Disease Point-of-care (POC) Diagnostics Forecast 2021-2028” has been featured on Fortune Business Insights™.

 

***Get Latest Updated Market Research Report with Free Sample Report

Market Overview

The global infectious disease point-of-care (POC) diagnostics market size is expected to gain momentum by reaching USD 3.96 billion by 2028 while exhibiting an impressive CAGR of 17.2% between 2021 to 2028. In its report titled “Infectious Disease Point-of-care (POC) Diagnostics Market, 2021-2028,” Fortune Business Insights mentions that the market stood at USD 1.12 billion in 2020.

Request for Free Sample Report PDF @ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/infectious-disease-point-of-care-poc-diagnostics-market-104307

 COVID-19 Impact

 

The COVID-19 pandemic has moderately affected the pharmaceutical sector and research institutes as these sectors are involved in developing POC kits for COVID-19 diagnosis. The immediate introduction of advanced products and ready-to-use test kits is driving market growth. For instance, in July 2020, B.D. (Becton, Dickinson, and Company) declared that the U.S. Food and Drug Administration (FDA) permitted Emergency Use Authorization (EUA) for rapid, point-of-care, SARS-CoV-2 diagnostic test for use with its broadly available BD Veritor Plus System. However, demand for several other test kits, such as MRSA, HIV, and CDI, declined due to the complete shift of companies on COVID kits and disruptions in the supply chain.  Thus, the market saw a decline in routine testing kits. However, the market is expected to revive during the forecast period.

 

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit:

Market Segmentation:

By technique, the market for infectious disease POC diagnostics is divided into lateral flow immunoassay, agglutination test, flow-through test, molecular diagnostics, and others.

 

  • Based on the technique, the lateral flow immunoassay segment held a share of 49.7% in 2020. This is attributable to increased research and products launch due to the COVID-19 virus. Furthermore, the availability of the test kits in decentralized settings is promoting the segment’s growth.

By disease, it is segmented into HIV, hepatitis B Virus, pneumonia/Streptococcus associated infections, respiratory syncytial virus (RSV), influenza, clostridium difficile infections (CDI), hepatitis C Virus, methicillin-resistant staphylococcus aureus (MRSA), tuberculosis, and others. By disease, COVID-19 Point-of-care diagnostics, by end-user it is segmented into hospital bedside, physician’s office lab, urgent care & retail clinics, home & self-testing, nursing homes, and Others. Finally, based on region, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

What does the Report Provide?

The market report for infectious disease point-of-care diagnostics provides a detailed analysis of several factors, such as the key drivers and restraints that will impact growth. Additionally, the report provides insights into the regional analysis that covers different regions, contributing to the growth of the market. It includes the competitive landscape that involves the leading companies and the adoption of strategies by them to introduce new products, announce partnerships, and collaboration that will further contribute to the market growth.

Driving Factor

Increasing Prevalence of Infectious Diseases to Spur Demand for Rapid POC Diagnostic Test Kits

 

The rising prevalence of viral diseases is expected to drive infectious disease point-of-care diagnostics market growth. For instance, a report by the United Nations Program on HIV/AIDS (UNAIDS) in 2019 states that around 38 million people suffer from HIV/AIDS. Another report by the World Health Organization (WHO) stated that in the year 2018, around 10 million people were affected by tuberculosis worldwide. Thus, the rising infection of the various diseases globally has spurred the demand for POC products for the diagnosis, and subsequently, its increased demand will favor the market during the forecast period.

 

Regional Insights

 

Rising Adoption of Advanced POC Diagnostic Kit in North America to Promote Growth

 

North America is expected to hold the largest infectious disease point-of-care (POC) diagnostics market share during the forecast period.  This is attributable to the rising adoption of advanced POC diagnostics kits to detect various infectious diseases. Additionally, increasing collaboration and strategic partnerships in the region will likely promote the regional market during the forecast period. For instance, in 2019, the U.S. Department of Health and Human Services (HHS) collaborated with Inflammatix Inc. The collaborations aim to develop a rapid diagnostic test to differentiate between bacterial and viral infections such as Flu, Sepsis, and offers test results in 20-30 minutes. North America stood at USD 0.41 billion in 2020.

 

On the other hand, Europe is expected to hold the second position in the market during the forecast period. This growth is attributable to the increasing investment in R&D activities by the companies in the region during the forecast period.

 

Competitive Landscape

 

Key Players to Focus on Partnerships to Strengthen Their Positions

 

The market for infectious disease point-of-care diagnostics is consolidated by major companies striving to maintain their position by focusing on partnerships and launching new products. For instance, in July 2020, Precipio Inc. strategically partnered with ADS Biotech to develop a lateral flow immunoassay-based COVID-19 detection kit. The project has received EUA permissions but awaiting USFDA approval for distributing the kits to the physician’s lab, retail pharmacies, and direct-to-customer. Moreover, other key players adopt proactive strategies such as acquisitions, mergers, and collaborations to favor the market’s growth in the upcoming years.

 

Industry Development

  • April 2021 – Chembio Diagnostics, Inc. launched of rapid point-of-care COVID-19 /Flu A&B test. The test is an extremely fast infectious disease point-of-care diagnostics test as it provides the results within 15 minutes.

Ask for Customization @ https://www.fortunebusinessinsights.com/enquiry/customization/infectious-disease-point-of-care-poc-diagnostics-market-104307

List of Key Players Profiled in this Market Report

 

  • Hoffmann-La Roche Ltd (Basel, Switzerland)
  • Thermo Fisher Scientific Inc. (Massachusetts, U.S.)
  • Abbott Laboratories (Illinois, U.S)
  • Quest Diagnostics Incorporated (New Jersey, United States)
  • D. (Franklin Lakes, U.S)
  • bioMérieux SA (Marcy l’Etoile, France)
  • Cardinal Health, Inc. (Ohio, U.S)
  • Mesa Biotech (California, U.S)
  • Cepheid (California, U.S)
  • Trinity Biotech (Bray, Ireland)
  • Quidel Corporation (San Diego, U.S.)
  • Bio-Rad Laboratories Inc. (California, U.S)

 

Table Of Content:

  1. Introduction
    • Market Scope
    • Market Segmentation
    • Market Methodology
    • Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  4. Key Insights

4.1 Prevalence of Key Infectious Diseases, By Key Countries

4.2 New Product Launches

4.3 Key Industrial Developments (Mergers, Acquisitions, Partnerships, etc.)

4.4 Technological Advancements in Infectious Disease Point-of-care (POC) Diagnostics

4.5 Impact of COVID-19 on Infectious Disease Point-of-care (POC) Diagnostics Market

4.6 Overview of Initiatives for Infectious Disease Point-of-care (POC) Diagnostics in Emerging Countries

4.7 Pricing Analysis of Various Infectious Disease Point-of-care (POC) Diagnostics, By Key Companies

4.8 Analysis of Product Features of Key Infectious Disease Point-of-care (POC) Diagnostics, By Key Companies

  1. Global Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

 5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Geography
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  1. North America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

 5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Country
    • S.
    • Canada
  1. Europe Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

 5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Country/Sub-region
    • K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  1. Asia Pacific Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

 5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Country/Sub-region
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  1. Latin America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

 5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Country/Sub-region
    • Brazil
    • Mexico
    • Rest of Latin America
  1. Middle East & Africa Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

 5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By Disease
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B Virus (HBV)
    • Pneumonia / Streptococcus Associated Infections
    • Respiratory Syncytial Virus (RSV)
    • Influenza
    • Clostridium difficile infection (CDI)
    • Hepatitis C Virus (HCV)
    • Methicillin-Resistant Staphylococcus Aureus (MRSA)
    • Tuberculosis (TB)
    • Others
  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Country/Sub-region
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  1. By Disease, COVID-19 Point of care (POC) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Technique

 5.2.1 Lateral Flow Immunoassay (LFIA)

5.2.2 Agglutination Tests

5.2.3 Flow-through Tests / Immunoconcentration Assays

5.2.4 Molecular Diagnostics

5.2.5 Others

  • Market Analysis, Insights and Forecast – By End User
    • Hospital Bedside
    • Physician’s Office Lab
    • Urgent Care & Retail Clinics
    • Home & Self-Testing
    • Nursing Homes
    • Others
  • Market Analysis, Insights and Forecast – By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  1. Competitive Analysis
    • Key Industry Developments
    • Global Market Share Analysis (2020)
    • Company Profiles (Overview, Product Types & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      • Hoffmann-La Roche Ltd
      • Thermo Fisher Scientific Inc.
      • Quest Diagnostics Incorporated
      • BD
      • bioMérieux SA
      • Cardinal Health, Inc.
      • Cepheid
      • Mesa Biotech
      • Trinity Biotech
      • Quidel Corporation
      • Bio-Rad Laboratories, Inc.
      • Abbott Laboratories
      • Other Prominent Players
  1. Strategic Recommendations

 

Continued. . .

Related Article @

https://marketresearchreportsfbi.wordpress.com/2021/11/08/autotransfusion-devices-market-by-technology-share-size-segmentation-revenue-analysis-forecast-2028/ 

https://www.theexpresswire.com/pressrelease/Dermatology-Drugs-Market-to-Reach-USD-6399-Billion-With-The-CAGR-129-During-the-Forecast-Period-2021-2028-Top-Companies-Share-Size-Growth_14683151

https://www.theexpresswire.com/pressrelease/Global-Asthma-Treatment-Market-Projection-by-Key-Players-Share-Size-Trends-Segmentation-Regional-Analysis-Industry-Growth-Forecast-2028_14842697 

https://www.theexpresswire.com/pressrelease/Global-Artificial-Tears-Market-Research-Report-by-Investment-In-The-Medical-Industry-Opportunity-And-Strategies-Forecast-2028_14843902 

https://www.theexpresswire.com/pressrelease/Dental-Prosthetics-Market-Projection-by-Technology-Top-Key-Players-Growth-Revenue-CAGR-Regional-Analysis-Industry-Forecast-2028_14842207 

https://www.marketwatch.com/press-release/global-point-of-care-ultrasound-research-report-by-investment-in-the-medical-industry-opportunity-and-strategies-forecast-2028-2021-12-03 

 

NOTE: Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. We aim to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

LinkedIn: https://www.linkedin.com/company/fortune-business-insights

Facebook: https://www.facebook.com/FortuneBusinessInsightsPvtLtd

Twitter: https://twitter.com/FBInsightPvtLtd

Showing 0 results
Your Answer

Please first to submit.

Get involved

Register

As a member of this site you will be able to receive aggregates news relating only to those categories that are most relevant to you, submit job listings for FREE, post questions in the Q&A, and more.

Register Now

Feature your company

The Feature Your Company listing is your custom-made (by us) profile page that allows you to add any of the following content: text, videos, links, images. The page will also be listed on the Featured Company landing page. Over 560 unique aggregates users visit the site per day! Complete the enquiry form now to contact us.

Contact us

Jobs

Are you looking for an aggregate related job? Click here to see our jobs listing supplied by industry experts United Employment.

See Jobs

Advertise

Reach thousands of budget holders and decision makers by promoting your company on the longest established aggregate website in the US & Canada. Or advertise in our emails which are sent to opted-in subscribers according to their chosen categories. All advertising will display correctly on tablets and mobiles as this site is responsive.